Abstract
Bioresorbable scaffolds (BRS) represent the latest revolution in interventional cardiology. Thanks to their reabsorptive properties, they provide temporary scaffolding that helps stabilizing the plaque and promotes healing, and then disappear, thus restoring a functional endothelium and vasomotion. Several devices have been tested at the preclinical and clinical stage. Here we review the rationale, development, design and clinical data of the BRS platforms, providing a comprehensive review of the literature.
Highlights
A Historical PerspectiveIn September 1977, Andreas Grüntzig, an ambitious young cardiologist from Zurich, performed the first coronary angioplasty on a severe stenosis of the left anterior descending artery in a conscious patient
Bioresorbable scaffolds (BRS) have been hailed as the fourth revolution in the history of interventional cardiology [21,22], since they provide temporary scaffolding that helps stabilizing the plaque and promotes healing, and disappear, leaving no trace behind
Even if several iterations of certain devices have been successfully developed and used in clinical practice, we are currently witnessing the introduction of the first-generation of BRS
Summary
In September 1977, Andreas Grüntzig, an ambitious young cardiologist from Zurich, performed the first coronary angioplasty on a severe stenosis of the left anterior descending artery in a conscious patient. The procedure was a complete success, and the patient— asymptomatic—was soon discharged [1]
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call